More children in the US are being given weight-loss drugs – including Wegovy

The number of children receiving Wegovy is increasing in the US.
More and more children in the US are taking the Novo Nordisk obesity drug, Wegovy. | Photo: Thomas Borberg
More and more children in the US are taking the Novo Nordisk obesity drug, Wegovy. | Photo: Thomas Borberg
by marketwire

In 2022, only 25 children were prescribed the drug. Wegovy was first approved in the US for use in adolescents in December of that year. And just a month later, the influential American Academy of Pediatrics recommended that children with obesity should be offered weight-loss medication from the age of 12.

Medicaid data obtained by Reuters from five states, including Michigan, Minnesota and Wisconsin, shows a similar increase in the use of Wegovy. The total number is still small, with at least 464 children across the five states having been prescribed the drug since January 2022.

The figure does not include prescriptions purchased without health insurance or off-label use of two similar treatments for type 2 diabetes, Ozempic from Novo and Mounjaro from Eli Lilly.

According to US government estimates, nearly 20% of US children, or about 14.7 million, are obese.

Being overweight has been linked to many serious health problems - including diabetes, heart disease and cancer.

(Translated using DeepL with additional editing by Katrine Gøthler)

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading